Abyssinia Biologics
Private Company
Funding information not available
Overview
Abyssinia Biologics is a preclinical-stage biotech developing highly selective monoclonal antibodies and a vaccine targeting toxic amyloid-beta oligomers for Alzheimer's disease. Founded in 2021 and operating with a virtual team, the company's platform aims to deliver greater clinical benefit with fewer side effects, such as ARIA, compared to plaque-clearing therapies. Its integrated strategy includes therapeutic, preventative, and diagnostic solutions, positioning it in the high-need, high-value neurodegenerative disease market, though it faces significant scientific, clinical, and competitive risks typical of early-stage CNS drug development.
Technology Platform
Platform for developing monoclonal antibodies and vaccines that selectively target conformational epitopes unique to toxic, soluble amyloid-beta oligomers while avoiding plaques and monomers.
Opportunities
Risk Factors
Competitive Landscape
Abyssinia competes in the crowded Alzheimer's space against approved plaque-clearing mAbs (lecanemab, donanemab) and numerous clinical-stage programs targeting amyloid, tau, and other pathways. Its differentiation hinges on oligomer selectivity, but it trails far behind commercial and late-stage competitors. Other companies are also exploring oligomer-targeting approaches, creating a subset of direct competitors.